Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead technology with Genetic Analysis of Oslo, Norway.

7 Jan 2014

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

Studies offer new insight into diverticulosis

Diverticulosis, a condition that develops when pouches form in the wall of the colon, is increasing in frequency. It affects the majority of those reaching the age of 80 - a growing portion of the population - and imposes a substantial burden on health-care resources, but curiously there is a lack of data and unanswered questions around this condition.

18 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

New research reveals novel way to develop anti-diarrhoeal drugs

New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.

11 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Dietary change should be considered in chronic prostatitis

Researchers from the USA say that physicians should consider dietary changes for patients with chronic prostatitis/chronic pelvic pain syndrome to improve symptoms.

21 Oct 2013

NIH funding helps develop chronic-pain network to accelerate research, treatments

What do migraine, irritable bowel syndrome, fibromyalgia and rheumatoid arthritis have in common? All involve chronic pain.

17 Oct 2013

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

For the first time, a simple blood test may be the best way to determine if a patient is suffering from Irritable Bowel Syndrome, or another serious condition such as Inflammatory Bowel Disease, according to Cedars-Sinai physician researcher Mark Pimentel, MD, lead author of a multicenter clinical trial.

17 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013

Viewpoints: 'Death throes' of health law opponents; Ryan's plan on entitlements may offer way out of budget crisis

Politically, the biggest challenges facing the ACA are behind us. By my count, the law has already survived three near-death experiences: the Democrats' loss of a filibuster-proof Senate majority with the election of Scott Brown in Jan. 2010, the Supreme Court's June 2012 decision upholding (with one exception) the law's constitutionality, and President Obama's re-election last Nov. Much of what we see going on in Washington now is the death throes of the opposition, especially now that Americans are beginning to sign up for coverage (John McDonough, 10/9).

11 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Studies offer new insight into diverticulosis

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

New research reveals novel way to develop anti-diarrhoeal drugs

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Researchers identify new drug for treating irritable bowel syndrome with constipation

Dietary change should be considered in chronic prostatitis

NIH funding helps develop chronic-pain network to accelerate research, treatments

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

IBS Treatment Center opens new clinic in Santa Monica, California

Viewpoints: 'Death throes' of health law opponents; Ryan's plan on entitlements may offer way out of budget crisis

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Woman suffering from chronic pelvic pain for nearly two decades now pain free

Hyperthyroidism sounds urinary problem alarm

Electroacupuncture treatment improves visceral hypersensitivity in irritable bowel syndrome

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in